Featured Press Releases

Developing innovative production technology for the commercialization of 3D cell products, PHC and Cyfuse collaborate

Developing innovative production technology for the commercialization of 3D cell products, PHC and Cyfuse collaborate

CollPlant Biotechnologies Announces First Quarter 2025 Financial Results and Issues Corporate Update

CollPlant Biotechnologies Announces First Quarter 2025 Financial Results and Issues Corporate Update

  • 28 May 2025

CollPlant Biotechnologies a regenerative and aesthetics medicine company developing innovative...

The U.S. FDA provides positive guidance on the Phase III trial of 64Cu-SAR-bisPSMA for recurrent prostate cancer.

The U.S. FDA provides positive guidance on the Phase III trial of 64Cu-SAR-bisPSMA for recurrent prostate cancer.

Mexico’s First Pharmaceutical Company, IFA Celtics, Deploys ForgeStop

Mexico’s First Pharmaceutical Company, IFA Celtics, Deploys ForgeStop's NFC Anti-Counterfeit Tech

At the American Thyroid Association meeting, FORE Biotherapeutics presented Phase 1/2a data for Plixorafenib, demonstrating a prolonged duration of effect in BRAF-altered thyroid cancers

At the American Thyroid Association meeting, FORE Biotherapeutics presented Phase 1/2a data for Plixorafenib, demonstrating a prolonged duration of effect in BRAF-altered thyroid cancers

Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

CollPlant Expands Its rhCollagen 3D Bioprinting Portfolio Through the Launch of Ready-to-Print BioFlex

CollPlant Expands Its rhCollagen 3D Bioprinting Portfolio Through the Launch of Ready-to-Print BioFlex

  • CollPlant
  • 24 Feb 2026
With timsOmni™ Mass Spectrometry, Bruker Advances Functional Proteomics 2.0 for Deeper Insights into Disease Biology

With timsOmni™ Mass Spectrometry, Bruker Advances Functional Proteomics 2.0 for Deeper Insights into Disease Biology

  • Bruker Corporation
  • 24 Feb 2026
SECuRE trial update: Another participant with negative PSMA PET and undetectable PSA

SECuRE trial update: Another participant with negative PSMA PET and undetectable PSA

  • Clarity Pharmaceuticals
  • 23 Feb 2026
PureTech Secures U.S. and EU Orphan Designations for Deupirfenidone (LYT-100) in IPF

PureTech Secures U.S. and EU Orphan Designations for Deupirfenidone (LYT-100) in IPF

  • PureTech Health plc
  • 20 Feb 2026
ENFLONSIA™ (clesrovimab) shows positive new results in infants and children under 2 at increased risk of severe RSV disease across two seasons, Merck reports

ENFLONSIA™ (clesrovimab) shows positive new results in infants and children under 2 at increased risk of severe RSV disease across two seasons, Merck reports

  • Merck & Co., Inc.
  • 19 Feb 2026
Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

  • P-Cure
  • 17 Feb 2026
World Drug Delivery Summit 2025
The Digital Pharma Advances Conference 2026

Most Popular
February   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.